Since the epidermis overlying cNF is normal, "there is no reason to use nonselective or surgical methods and destroy a perfectly good epidermis when you don t need to," Patricia Richey, MD, said.
Revance to Present Clinical Da - GuruFocus.com gurufocus.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from gurufocus.com Daily Mail and Mail on Sunday newspapers.
Revance Reports Positive Efficacy and Duration Results from Phase 2 Upper Facial Lines Study
Revance Reports Positive Efficacy and Duration Results from Phase 2 Upper Facial Lines Study Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced positive topline efficacy and safety results from its Phase 2 multicenter, open-label study of investigational drug candidate DaxibotulinumtoxinA for Injection for the combined treatment of upper facial lines, which are comprised of glabellar (frown) lines (GL), dynamic forehead lines (FHL) and lateral canthal lines (LCL), commonly known as crows feet lines. In the Phase 2 study, 48 subjects were enrolled to receive a single treatment of DaxibotulinumtoxinA for Injection with a total study duration of 36 weeks. Subjects received 40, 32, and 48 units of DaxibotulinumtoxinA for Injection respectively in the glabellar complex, forehead and lateral canthal are